Merck lowers mid-term healthcare outlook after recent drug failures
German science and technology company Merck lowered mid-term targets for its Life Sciences and Healthcare businesses, ...
Merck KGaA Boss Is Scoffing at the Obesity Hype: Leader Q&A
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BioSpace5h
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...
FierceBiotech22h
With trial win, Merck's RSV antibody clesrovimab looks poised to take on Sanofi and AZ's Beyfortus
Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.
FiercePharma10d
Merck's Keytruda stages comeback in head and neck cancer with trial win in earlier-stage disease
Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...
Merck Escapes Antitrust Liability in Suit Over Its Mumps Vaccine
Merck & Co. escaped antitrust claims by a group physicians who alleged that they bought the company’s mumps vaccine at inflated prices because it deceived the government to maintain its monopoly on ...
Merck's Clesrovimab Lowers RSV Disease And Hospitalization In Preterm And Full-term Infants
Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...
Merck Is At Support And Should Go Higher (Technical Analysis)
Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...
DPA International on MSN1d
German science and tech giant Merck confirms full-year guidance
German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a ...